The Vanguard Group 13D and 13G filings for Eagle Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:04 pm Sale | 2023-12-29 | 13G | Eagle Pharmaceuticals, Inc. EGRX | The Vanguard Group | 638,124 4.910% | -125,683 (-16.45%) | Filing |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | Eagle Pharmaceuticals, Inc. EGRX | The Vanguard Group | 763,807 5.870% | 3,339 (+0.44%) | Filing |
| 2022-02-09 3:43 pm Sale | 2021-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | The Vanguard Group | 760,468 5.890% | -4,467 (-0.58%) | Filing |
| 2021-02-10 10:52 am Purchase | 2020-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | The Vanguard Group | 764,935 5.870% | 4,565 (+0.60%) | Filing |
| 2020-02-11 4:44 pm Purchase | 2019-12-31 | 13G | Eagle Pharmaceuticals, Inc. EGRX | The Vanguard Group | 760,370 5.560% | 760,370 (New Position) | Filing |